Treatment of SCLC cells with an LSD1 inhibitor revealed that sensitivity to this drug could be predicted by the expression levels of members of the MYC family of transcription factors, including MYCL, MYCN, and MYC. This evidence concerns the gene MYCN and small cell lung carcinoma.